Article
Development of resistance to passive therapy with a potently neutralizing humanized monoclonal antibody against West Nile virus.
The Journal of infectious diseases - 15 Jul 2009
Zhang Shuliu, Vogt Matthew R, Oliphant Theodore, Engle Michael, Bovshik Evgeniy I, Diamond Michael S, Beasley David W C
Abstract excerpt
Previous studies have established the therapeutic efficacy of humanized E16 (hE16) monoclonal antibody against West Nile virus in animals. Here, we assess the potential for West Nile virus strains encoding mutations in the hE16 epitope to resist passive immunotherapy and for the selection of neutralization escape variants during hE16 treatment. Resistance to hE16 in vivo was less common than expected, because...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.